Crosstalk events in the estrogen signaling pathway may affect tamoxifen efficacy in breast cancer molecular subtypes
- 1 December 2015
- journal article
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 59, 42-54
Abstract
No abstract availableKeywords
Funding Information
- CONACyT (179431/2012)
- CONACyT (420970)
This publication has 51 references indexed in Scilit:
- The current state of breast cancer classificationAnnals of Oncology, 2012
- A refined molecular taxonomy of breast cancerOncogene, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Integrated Quantitative Analysis of the Phosphoproteome and Transcriptome in Tamoxifen-resistant Breast CancerJournal of Biological Chemistry, 2011
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survivalProceedings of the National Academy of Sciences of the United States of America, 2005
- Antiestrogen resistance in breast cancer and the role of estrogen receptor signalingOncogene, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- KEGG: Kyoto Encyclopedia of Genes and GenomesNucleic Acids Research, 2000
- The Hallmarks of CancerCell, 2000